Cipla Suspends Effort To Buy Majority Of South Africa's Cipla Medpro
This article was originally published in PharmAsia News
Executive Summary
Cipla has suspended its effort to buy a majority stake in the South Africa drug maker Cipla Medpro that shares its name, citing issues concerning its valuation.
You may also be interested in...
FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
Need a specific report? 1000+ reports available
Buy Reports